The federal 340B drug discount program is essential to helping safety net providers meet their missions to treat the underserved. The program is under heavy attack in Washington, DC by the drug industry, which wants to gut it to maximise profits. At … [Read more...]
News & Commentary
Three Proposals That Would Kill the 340B Program
September 27, 2018 by
In the December issue of Evidence-Based Oncology, Rena M. Conti, PhD; Peter B. Bach, MD, MAPP; and Michael Kolodziej, MD, laid out 3 proposals to reform the 340B Drug Discount Program. However, their prescriptions would effectively cause the … [Read more...]
Setting the Record Straight on Drug Shortages
September 27, 2018 by
John Goodman of the National Center for Policy Analysis (NCPA) says in a June 8 Health Affairs Blog entry that the Public Health Service 340B drug discount program is part of a "web of [federal] regulations that are preventing life saving drugs from … [Read more...]